Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results

Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results

Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, in particular those receiving anti-B cell therapy with rituximab (RTX), the post-vaccination effect may be insufficient. Since 2022 the long-acting virus-neutraliz...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Beketova, N. O. Levina, Yu. A. Uskova, I. V. Rozanova, M. V. Dubinskaia, S. A. Evdokimova, V. V. Babak, M. F. Beketova, A. V. Devyatkin
Format: Article
Language:Russian
Published: IMA PRESS LLC 2024-11-01
Series:Научно-практическая ревматология
Subjects:
tixagevimab
cilgavimab
virus-neutralizing monoclonal antibodies
covid-19
rituximab
anca-associated systemic vasculitis
inflammatory rheumatic diseases
Online Access:https://rsp.mediar-press.net/rsp/article/view/3632
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://rsp.mediar-press.net/rsp/article/view/3632

Similar Items